Nurix Therapeutics to Participate in Upcoming Investor Conferences
Nurix Therapeutics (Nasdaq: NRIX), a clinical-stage biopharmaceutical company specializing in targeted protein degradation medicines for cancer and inflammatory diseases, has announced its participation in two major investor conferences in March 2025.
The company's leadership, including President and CEO Arthur T. Sands, M.D., Ph.D., and CFO Hans van Houte, will attend the Jefferies Biotech on the Beach Summit in Miami Beach for one-on-one meetings on March 11, 2025. They will also participate in the Barclays 27th Annual Global Healthcare Conference in Miami Beach, featuring a fireside chat on March 12, 2025, from 10:00-10:25 a.m. ET.
The fireside chat will be accessible through a live webcast on the Investors section of Nurix's website, with the recording available for 30 days following the event.
Nurix Therapeutics (Nasdaq: NRIX), un'azienda biofarmaceutica in fase clinica specializzata in medicinali per la degradazione mirata delle proteine per il cancro e le malattie infiammatorie, ha annunciato la sua partecipazione a due importanti conferenze per investitori a marzo 2025.
La leadership dell'azienda, tra cui il Presidente e CEO Arthur T. Sands, M.D., Ph.D. e il CFO Hans van Houte, parteciperà al Jefferies Biotech on the Beach Summit a Miami Beach per incontri one-on-one l'11 marzo 2025. Parteciperanno anche alla 27ª Conferenza Globale Annuale sulla Salute di Barclays a Miami Beach, con una chiacchierata informale il 12 marzo 2025, dalle 10:00 alle 10:25 a.m. ET.
La chiacchierata informale sarà accessibile tramite una diretta streaming nella sezione Investitori del sito web di Nurix, con la registrazione disponibile per 30 giorni dopo l'evento.
Nurix Therapeutics (Nasdaq: NRIX), una empresa biofarmacéutica en etapa clínica especializada en medicamentos de degradación dirigida de proteínas para el cáncer y enfermedades inflamatorias, ha anunciado su participación en dos importantes conferencias para inversores en marzo de 2025.
El liderazgo de la empresa, incluyendo el Presidente y CEO Arthur T. Sands, M.D., Ph.D. y el CFO Hans van Houte, asistirá al Jefferies Biotech on the Beach Summit en Miami Beach para reuniones uno a uno el 11 de marzo de 2025. También participarán en la 27ª Conferencia Global Anual de Salud de Barclays en Miami Beach, que contará con una charla informal el 12 de marzo de 2025, de 10:00 a 10:25 a.m. ET.
La charla informal estará disponible a través de una transmisión en vivo en la sección de Inversores del sitio web de Nurix, con la grabación disponible durante 30 días después del evento.
Nurix Therapeutics (Nasdaq: NRIX)는 암 및 염증 질환을 위한 표적 단백질 분해 의약품을 전문으로 하는 임상 단계의 생명공학 회사로, 2025년 3월에 두 개의 주요 투자자 회의에 참여한다고 발표했습니다.
회사의 리더십, 회장 겸 CEO Arthur T. Sands, M.D., Ph.D.와 CFO Hans van Houte를 포함하여, 2025년 3월 11일 마이애미 비치에서 열리는 Jefferies Biotech on the Beach Summit에 참석하여 일대일 회의를 진행할 예정입니다. 또한 2025년 3월 12일 오전 10시부터 10시 25분(ET)까지 마이애미 비치에서 열리는 Barclays 제27회 연례 글로벌 헬스케어 회의에도 참여할 것입니다.
이 대화는 Nurix 웹사이트의 투자자 섹션을 통해 실시간으로 스트리밍될 예정이며, 이벤트 후 30일 동안 녹화본이 제공됩니다.
Nurix Therapeutics (Nasdaq: NRIX), une entreprise biopharmaceutique en phase clinique spécialisée dans les médicaments de dégradation ciblée des protéines pour le cancer et les maladies inflammatoires, a annoncé sa participation à deux grandes conférences pour investisseurs en mars 2025.
La direction de l'entreprise, y compris le Président et CEO Arthur T. Sands, M.D., Ph.D. et le CFO Hans van Houte, assistera au Jefferies Biotech on the Beach Summit à Miami Beach pour des réunions individuelles le 11 mars 2025. Ils participeront également à la 27e Conférence Annuelle Mondiale sur la Santé de Barclays à Miami Beach, qui comprendra une discussion informelle le 12 mars 2025, de 10h00 à 10h25 ET.
La discussion informelle sera accessible via un webcast en direct dans la section Investisseurs du site web de Nurix, avec un enregistrement disponible pendant 30 jours après l'événement.
Nurix Therapeutics (Nasdaq: NRIX), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Medikamente zur gezielten Proteinabbau für Krebs und entzündliche Erkrankungen spezialisiert hat, hat seine Teilnahme an zwei wichtigen Investorenkonferenzen im März 2025 angekündigt.
Die Unternehmensführung, darunter Präsident und CEO Arthur T. Sands, M.D., Ph.D. und CFO Hans van Houte, wird am Jefferies Biotech on the Beach Summit in Miami Beach am 11. März 2025 für persönliche Gespräche teilnehmen. Außerdem werden sie an der 27. jährlichen globalen Gesundheitskonferenz von Barclays in Miami Beach teilnehmen, die am 12. März 2025 von 10:00 bis 10:25 Uhr ET eine informelle Gesprächsrunde bietet.
Die informelle Gesprächsrunde wird über einen Live-Stream im Investorenbereich der Nurix-Website zugänglich sein, und die Aufzeichnung wird 30 Tage nach der Veranstaltung verfügbar sein.
- None.
- None.
SAN FRANCISCO, March 04, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, and Hans van Houte, chief financial officer of Nurix, will participate in the following conferences in March.
- Jefferies Biotech on the Beach Summit, Miami Beach, FL
- One-on-one meetings only: March 11, 2025
- Barclays 27th Annual Global Healthcare Conference, Miami Beach, FL
- Fireside chat: March 12, 2025, from 10:00-10:25 a.m. ET
The fireside chat will be webcast live and may be accessed via a link in the Investors section of the Nurix website. The archived webcast will be available for 30 days after the event.
About Nurix Therapeutics, Inc.
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases. Nurix’s wholly owned, clinical stage pipeline includes degraders of Bruton’s tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix also is advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Nurix’s partnered drug discovery pipeline consists of preclinical stage degraders of IRAK4 and STAT6, as well as multiple additional programs under collaboration agreements with Gilead Sciences, Inc., Sanofi S.A. and Pfizer Inc., within which Nurix retains certain options for co-development, co-commercialization and profit sharing in the United States for multiple drug candidates. Powered by a fully AI-integrated discovery engine capable of tackling any protein class, and coupled with unparalleled ligase expertise, Nurix’s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine’s next chapter with a new script to outmatch disease. Nurix is headquartered in San Francisco, California. For additional information visit http://www.nurixtx.com.
Contacts:
Investors
Jason Kantor, Ph.D.
Nurix Therapeutics, Inc.
ir@nurixtx.com
Elizabeth Wolffe, Ph.D.
Wheelhouse Life Science Advisors
lwolffe@wheelhouselsa.com
Media
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
FAQ
When is Nurix Therapeutics (NRIX) presenting at the Barclays Healthcare Conference in March 2025?
How can investors access Nurix's (NRIX) Barclays Conference presentation?
Which investor conferences is Nurix Therapeutics (NRIX) attending in March 2025?
What type of medicines is Nurix Therapeutics (NRIX) developing?
